drugset / Trial / NCT01871493
A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants
Non-randomizedSingle-groupOpen-labelBasic science
Summary
The main purpose of this study is to evaluate how the body absorbs and removes LY2605541, insulin lispro, and a mixture of both from the blood. The study has two parts. Participants may enroll in only one part. Each part has four treatment periods in a fixed order. The study will last approximately 8 weeks, not including screening. Screening is required within 28 days prior to the start of the study.
Timeline
- Start
- 2013-06
- Primary completion
- 2013-09
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin Lispro | Protein / enzyme biologic | 0.18 iu/kg | Subcutaneous |
| Subject | Insulin Lispro | Protein / enzyme biologic | 0.36 iu/kg | Subcutaneous |
| Subject | Insulin Peglispro | Protein / enzyme biologic | 0.54 iu/kg | Subcutaneous |
| Subject | Insulin Peglispro | Protein / enzyme biologic | 0.71 iu/kg | Subcutaneous |
| Subject | Insulin Peglispro | Protein / enzyme biologic | 1.42 iu/kg | Subcutaneous |
Indications
No indication recorded.